secwatch.observer — SEC 8-K summary
======================================

Issuer:     SANGAMO THERAPEUTICS, INC (SGMO)
CIK:        0001001233
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001001233-25-000023
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sangamo Q3 net loss $34.9M, revenue $0.6M; advancing Fabry BLA and pain trial enrollment
--------------------------------------------------------------------------------

- Q3 2025 consolidated net loss $34.9M ($0.11/sh) vs net income $10.7M ($0.04/sh) in prior year.
- Revenue of $0.6M down from $49.4M, mainly due to absence of Genentech collaboration revenue.
- Cash and equivalents $29.6M; with Pfizer $6M license fee and ATM proceeds, runway into Q1 2026.
- FDA reiterated eGFR slope endpoint for isaralgagene civaparvovec accelerated approval; BLA submission expected as early as Q1 2026.
- First two clinical sites activated for Phase 1/2 ST-503 chronic neuropathic pain study; first patient dosing expected in coming months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001233/000100123325000023/0001001233-25-000023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001233/000100123325000023/sgmo-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001001233-25-000023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer